Phase
Condition
Lung Disease
Lung Injury
Cystic Fibrosis
Treatment
N/AClinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
The patients who were started Pirfenidone or Nintedanib treatment with the diagnosisof Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis according to AnOfficial ATS/ERS/JRS/ALAT Clinical Practice guideline and treated for at least oneyear in our department between January 1 2010 and December 31 2022 The includedpatients had not previously used steroids or similar drugs for lung disease.
Patients aged 18 years who have not used steroids or similar medication afterdiagnosis
Exclusion
Exclusion Criteria:
Patients whose radiologic and PFT data at initial presentation were not available -Patients whose treatment was discontinued before 1 year due to side effects orunresponsiveness or death
Patients who were switched between the two drugs before 1 year had elapsed
Study Design
Study Description
Connect with a study center
1. Karadeniz Technical University Faculty of Medicine, Department of Chest Diseases
Trabzon, 61100
TurkeySite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.